Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lumiera Health (NHP) recorded a 30 per cent increase in Q4 2021 versus Q4 2020
  • The company saw a 59 per cent sales increase in November 2021 versus November 2020
  • Sales for the year increased by 10 per cent over 2020
  • Lumiera Health specializes in the development and commercialization of consumer products for the natural health industry
  • Lumiera Health Inc. (NHP) is unchanged on the day, trading at C$0.02 per share at 11:20 am EST

Lumiera Health (NHP) is pleased to announce that the new corporate strategy that was put in place Q1-Q3 2021 has been successful.

Carlos Ponce, CEO of Lumiera Health sat down with Caroline Egan to discuss the results.

Lumiera’s fiscal Q4 was a record quarter with sales up by 30 per cent vs Q4 2020, highlighted by a record 59.3 per cent sales increase in November 2021 over November 2020.

The increase in sales and strong quarter-over-quarter growth was driven by the success of expanded distribution, new digital and retail marketing campaigns, and the performance of a new sales and in-store training team put in place earlier in the year.

Lumiera Health specializes in the development and commercialization of consumer products for the natural health industry. 

Lumiera Health Inc. (NHP) is unchanged on the day, trading at C$0.02 per share at 11:20 am EST.

More From The Market Herald

" @ the Bell: TSX plunges as oil drops

Canada’s main stock index closed out the week in the red on Friday in a broad decline.
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" As the market falls, investors turn to tech stocks

Canadians received news from Statistics Canada this week that inflation dropped to 7.0 per cent in August.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.